Parabilis Medicines PBLS
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 75th percentile, 5-year average -16.8x
Above its usual level · 68th percentile, 5-year average -0.4x
#3982 of 5330 stocks by PB (1 = cheapest)
Above its usual level · 62nd percentile, 5-year average 15,611.9x
#5149 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 3.55 | – | -0.40 | 68% (pricier than usual) | #3982 of 5330 (1 = cheapest) |
| PE | -15.14 | -18.36 | -16.79 | 75% (pricier than usual) | – |
| PS | 24,061.35 | 736.78 | 15,611.86 | 62% (pricier than usual) | #5149 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on PBLS.
Sign in to join the discussion.